US 2026/0217813 A1Published application

Anti-Human P40 Protein Domain Antibody And Use Thereof

AssigneeAkeso Biopharma, Inc.

InventorsYu Xia, Zhongmin Maxwell Wang, Peng Zhang, Baiyong Li

Life of this patent

Estimating the term…

Abstract

The present invention relates to an antibody for treating or preventing autoimmune diseases. The antibody of the present invention comprises a heavy chain variable region set forth in SEQ ID NO:1 or SEQ ID NO:24 and a light chain variable region set forth in SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17 or SEQ ID NO:25.

Claims20

Dependent claims

An antibody or an antigen-binding fragment thereof, wherein the antibody comprises:

(1) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:
1 which comprises HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:1, and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:6 which comprises LCDR1 of SEQ ID NO:8, LCDR2 of SEQ ID NO:9 and LCDR3 of SEQ ID NO:10, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:6,
(2) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:
1 which comprises HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:1;
and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:11 which comprises LCDR1 of SEQ ID NO:
19, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:22, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:11,
(3) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:1 which comprises HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:1;
and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:13 which comprises LCDR1 of SEQ ID NO:
20, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:22, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:13,
(4) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:
1 which comprises HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:1;
and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:15 which comprises LCDR1 of SEQ ID NO:
20, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:22, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:15,
(5) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:
1 which comprises HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:1;
and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:17 which comprises LCDR1 of SEQ ID NO:
20, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:23, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:17, or
(6) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:24 which comprises HCDR1 of SEQ ID NO:
26, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:24;
and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:25 which comprises LCDR1 of SEQ ID NO:
27, LCDR2 of SEQ ID NO:28 and LCDR3 of SEQ ID NO:22, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:25, wherein the antigen-binding fragment is selected from the group consisting of:
Fab, Fab′, F(ab′)2, Fv, Fab/c, single chain antibody, and bivalent antibody.

49 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/399,171Filed 24 Nov 2025
Priority: CN 201910706137.130 Jul 2019
Published: 30 Jul 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61P 1/00
Drugs for disorders of the alimentary tract or the digestive system
C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
A61K 47/6845
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a cytokine, e.g.…
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…

Family

Application17/631,797Continuation · filed 28 Jul 2020
Application19/399,171Continuation
US 12,595,300 B2Related patent
US 2022/0298235 A1Published application
US 2026/0217813 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An antibody or an antigen-binding fragment thereof, wherein the antibody comprises:

(1) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:
1 which comprises HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:1, and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:6 which comprises LCDR1 of SEQ ID NO:8, LCDR2 of SEQ ID NO:9 and LCDR3 of SEQ ID NO:10, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:6,
(2) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:
1 which comprises HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:1;
and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:11 which comprises LCDR1 of SEQ ID NO:
19, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:22, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:11,
(3) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:1 which comprises HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:1;
and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:13 which comprises LCDR1 of SEQ ID NO:
20, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:22, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:13,
(4) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:
1 which comprises HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:1;
and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:15 which comprises LCDR1 of SEQ ID NO:
20, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:22, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:15,
(5) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:
1 which comprises HCDR1 of SEQ ID NO:3, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:1;
and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:17 which comprises LCDR1 of SEQ ID NO:
20, LCDR2 of SEQ ID NO:21 and LCDR3 of SEQ ID NO:23, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:17, or
(6) a heavy chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:24 which comprises HCDR1 of SEQ ID NO:
26, HCDR2 of SEQ ID NO:4 and HCDR3 of SEQ ID NO:5, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:24;
and
a light chain variable region comprising or consisting of:
an amino acid sequence set forth in SEQ ID NO:25 which comprises LCDR1 of SEQ ID NO:
27, LCDR2 of SEQ ID NO:28 and LCDR3 of SEQ ID NO:22, or
a sequence having at least 80% sequence identity to the sequence set forth in SEQ ID NO:25, wherein the antigen-binding fragment is selected from the group consisting of:
Fab, Fab′, F(ab′)2, Fv, Fab/c, single chain antibody, and bivalent antibody.

49 more elements

Facts

Application

19/399,171Filed 24 Nov 2025

Priority

CN 201910706137.130 Jul 2019

Published

30 Jul 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61P 1/00
Drugs for disorders of the alimentary tract or the digestive system
C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
A61K 47/6845
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a cytokine, e.g.…
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…